Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on β-blockers

Simmons, Steven T.; Earl, Melissa

doi:10.1016/s0161-6420(01)00936-8

Cited by 40 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…179 In subjects (n = 115) with uncontrolled IOP on β-blocker monotherapy, adjunctive latanoprost (23.5%) or brimonidine (22.8%) were comparable in%IOPR at peak effect at one month, but brimonidine was better tolerated than latanoprost. 151 As third-line agents, overall mean%IOPR was not significantly different between brimonidine (22.8%) and latanoprost (17.2%), although brimonidine (85%) had slightly higher although non-significant clinical success ($15% reduction in IOP from baseline) than latanoprost (65%). 152 An additive effect of latanoprost was seen in an openlabel 1-week trial of subjects with uncontrolled IOP on concomitant timolol and dorzolamide twice daily 184 with an additional 16% reduction in IOP, and a 3-month study of subjects with uncontrolled IOP on fixed combination dorzolamide/timolol (FCDT) with a further 5.2 mmHg IOP reduction at peak and 3.5 mmHg at trough.…”

Section: Adjunctive Therapymentioning

confidence: 87%

“…Head-to-head trials post-dated the study hence studies comparing the medication in question and timolol 71-73, 81,116,119,147,148 or betaxolol 149 were included. In contrast, head-to-head trials, 43,52,53,59,70,76,77,83,[150][151][152][153][154][155][156][157] only were analyzed for the second meta-analysis. 146 The pooled summary estimate significantly favored latanoprost (weighted mean difference (WMD) = 1.10, 95% CI 0.57 to 1.63) over brimonidine.…”

Section: Vs Brimonidinementioning

confidence: 99%

See 1 more Smart Citation

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2α. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOPlowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1-to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.

show abstract

Section: Adjunctive Therapymentioning

confidence: 87%

Section: Vs Brimonidinementioning

confidence: 99%

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

show abstract

“…Tek ilaçla kontrol altına alınamayan yüksek GİB'e sahip ve hedef GİB oldukça düşük tutulması gereken hastalarda kombine tedavi cerrahiden önceki son seçenektir [9].…”

Section: Discussionunclassified

To evaluate the effectiveness of latanoprost and dorsolamide/timolol fixed combination therapy as initial treatment for glaucoma patients with high intraocular pressure

Bılgın

Kayıkçıoğlu²,

Başer³

2014

J Clin Exp Invest

View full text Add to dashboard Cite

Objective: To evaluate the effectiveness of latanoprost and dorsolamide-timolol fixed combination therapy as initial treatment for treatment naïve patients with intraocular pressure (IOP) values over 30 mm Hg. Methods:Twenty-five eyes of 25 newly diagnosed patients whose IOP measurements were at least 30 mmHg and who did not receive any antiglaucomatous medication previously were included in the study. Sixteen eyes had primary open angle glaucoma and 9 eyes had pseudoexfoliation glaucoma. Visual acuity, iridocorneal angle, intraocular pressure, optic nerve head and computerized visual field test were evaluated in each patient. Patients were evaluated on the first and third months of therapy for IOP reduction and ocular side effects. Results:The baseline average IOP was 38.4 ± 7.0 mmHg initially, at first month average IOP was 16.3± 3.7mmHg and at third month average IOP was 18.6 ± 4.2 mmHg. IOP reduction from baseline was 22.1 ± 9.0 mmHg (55.7± 14.5 %) for the first month, 19.8 ± 8.9 mmHg (49.6 ± 15.9 %) for the third month (p=0.0001) None of the patients reported any serious side-effects about therapy. Five (20%) had moderate hyperemia, 2 (8%) reported metallic taste. Conclusion:The combined therapy of latanoprost and dorsolamide/timolol fixed combination as initial treatment for intraocular pressure over 30 mmHg is highly efficient and well tolerated for treatment naive glaucoma. Yöntemler: Çalışmaya yeni tanı almış ve daha önce glokom tedavisi uygulanmamış, göz içi basıncı ölçümü 30 mmHg ve üzerinde olan 25 hasta dahil edildi. On altı gözde primer açık açılı glokom, 9 gözde psödoeksfolias-yon glokomu mevcuttu. Görme keskinliği, göz içi basıncı (GİB), bilgisayarlı görme alanı ölçümleri, iridokorneal açı ve optik sinir başını içeren oftalmolojik muayeneleri yapıl-dı. Hastalar tedavinin 1. ve 3.ayında GİB düşüşü ve yan etki profili açısından değerlendirildi. Bulgular: Başlangıç GİB değeri ortalama 38,4 ± 7 mmHg, 1. ay GİB değeri ortalama 16,3 ± 3,7 mmHg ve 3. ay GİB değeri ortalama 18,6 ± 4,2 mmHg olarak saptandı. Baş-langıç GİB değerine göre 1. ayda 22,1 ± 9 mmHg (%55,7 ± 14,5), üçüncü ayda 19,8 ± 8,9 mmHg (%49,6 ± 15,9) düşüş sağlandı (p=0,0001). Hastaların hiçbirinde ciddi yan etki görülmedi. Beş (%20) hastada hafif hiperemi gözlenirken, iki (%8) hastada ağızda metalik tat şikayeti ile karşılaşıldı.Sonuç: Göz içi basıncı 30 mmHg'nın üzerindeki hastalarda başlangıç tedavisi olarak latanoprost ve dorzolamid/ timolol sabit kombinasyonun erken dönemde oldukça etkili olduğunu ve yan etki profili açısından tolere edilebilir olduğunu söyleyebiliriz.Anahtar kelimeler: Dorzolamid, latanoprost, timolol, psödoeksfoliasyon glokomu, primer açık açılı glokom

show abstract

“…Topical beta-blockers may decrease plasma HDL Ievels [28]. Several reports have demonstrated that the use of topical beta-blockers may negatively impact patients' quality of life by causing exercise intolerance, sexual dysfunction, and respiratory difficulty [21,29].…”

Section: Beta-blockers As Ocular Hypotensive Agents: a Historymentioning

confidence: 99%

“…Brimonidine lowers IOP by a dual mechanism of action: increasing uveoscleral outflow and decreasing aqueous humor production [51]. Numerous clinical trials have demonstrated the efficacy of brimonidine as both monotherapy and adjunctive therapy [29,38,[52][53][54]. Although indicated as a thrice-daily medication in the United States, brimonidine is most frequently prescribed as a twice-daily medication.…”

Section: Selective Alpha2 Agonist: Brimonidinementioning

confidence: 99%

Evolving Paradigms in the Medical Treatment of Glaucoma

2004

View full text Add to dashboard Cite

In the last 5 years, numerous novel ocular hypotensive agents have been introduced for the control of intraocular pressure (IOP). Clinicians now have more options than ever in medical therapy for the treatment of glaucoma and ocular hypertension. When selecting an ocular hypotensive medication for their patients, clinicians should consider not only the IOP-lowering efficacy of an agent but also the ability of the drug to achieve target levels of IOP that are low enough to stop the progression of glaucomatous damage. Other considerations should include how well the drug controls diurnal IOP, the likelihood of serious adverse events, the versatility of the medication for use as an adjunctive agent, as well as other potential attributes (e.g., neuroprotection).

show abstract

Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on β-blockers

Cited by 40 publications

References 26 publications

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

To evaluate the effectiveness of latanoprost and dorsolamide/timolol fixed combination therapy as initial treatment for glaucoma patients with high intraocular pressure

Evolving Paradigms in the Medical Treatment of Glaucoma

Contact Info

Product

Resources

About